Patents Assigned to AVIDITY BIOSCIENCES, INC.
  • Compositions and methods of treating facioscapulohumeral muscular dystrophy
    Patent number: 11912779
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating facioscapulohumeral muscular dystrophy (FSHD).
    Type: Grant
    Filed: September 15, 2022
    Date of Patent: February 27, 2024
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Barbora Malecova, Rob Burke, Beatrice Diana Darimont, David Sala Cano
  • Compositions and methods of treating muscle atrophy and myotonic dystrophy
    Patent number: 11872287
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
    Type: Grant
    Filed: September 27, 2022
    Date of Patent: January 16, 2024
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Michael Hood, Beatrice Diana Darimont, Rob Burke, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Anti-transferrin receptor antibodies and uses thereof
    Patent number: 11834510
    Abstract: Disclosed herein, in certain embodiments, are anti-transferrin receptor antibodies, anti-transferrin receptor antibody conjugates, and pharmaceutical compositions which comprise the anti-transferrin receptor antibodies or conjugates. In some embodiments, also disclosed herein are methods of delivering a payload utilizing an anti-transferrin receptor antibody described herein, and methods of treatment with use of an anti-transferrin receptor antibody described herein.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: December 5, 2023
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Beatrice Diana Darimont, Venkata Ramana Doppalapudi, Rachel Johns
  • Compositions and methods of treating muscle atrophy and myotonic dystrophy
    Patent number: 11712478
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: August 1, 2023
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Michael Hood, Beatrice Diana Darimont, Rob Burke, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Compositions and methods of treating muscle dystrophy
    Patent number: 11707532
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: July 25, 2023
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Venkata Ramana Doppalapudi, Michael David Hood, Rob Burke, Michael Caramian Cochran, Beatrice Diana Darimont, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Nucleic acid-polypeptide compositions and uses thereof
    Patent number: 11578090
    Abstract: Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 14, 2023
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Venkata Ramana Doppalapudi, Michael Caramian Cochran, David Sai-Ho Chu, Joel Daniel Arias, Rob Burke
  • Compositions and methods of treating muscle atrophy and myotonic dystrophy
    Patent number: 11576980
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: February 14, 2023
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Michael Hood, Beatrice Diana Darimont, Rob Burke, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Compositions and methods of treating Facioscapulohumeral muscular dystrophy
    Patent number: 11555190
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: January 17, 2023
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Barbora Malecova, Rob Burke, David Sala Cano, Beatrice Diana Darimont
  • Compositions and methods of treating muscle atrophy and myotonic dystrophy
    Patent number: 11554176
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: January 17, 2023
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Michael Hood, Beatrice Diana Darimont, Rob Burke, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Compositions and methods of treating Facioscapulohumeral muscular dystrophy
    Patent number: 11525137
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating Facioscapulohumeral muscular dystrophy.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: December 13, 2022
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Barbora Malecova, Rob Burke, David Sala Cano, Beatrice Diana Darimont
  • Compositions and methods of treating muscle atrophy and myotonic dystrophy
    Patent number: 11497814
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: November 15, 2022
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Michael Hood, Beatrice Diana Darimont, Rob Burke, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Compositions and methods of treating muscle dystrophy
    Patent number: 11446387
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: September 20, 2022
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Venkata Ramana Doppalapudi, Michael David Hood, Rob Burke, Michael Caramian Cochran, Beatrice Diana Darimont, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Nucleic acid-polypeptide compositions and methods of inducing exon skipping
    Patent number: 11400163
    Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: August 2, 2022
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Arthur A. Levin, Andrew John Geall, Venkata Ramana Doppalapudi, Michael Caramian Cochran, Hanhua Huang, Rob Burke
  • Nucleic acid-polypeptide compositions and uses thereof
    Patent number: 11364302
    Abstract: Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: June 21, 2022
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, Joel Daniel Arias, David Sai-Ho Chu, Michael Caramian Cochran, Rob Burke, Philip Kovach, Barbora Malecova
  • Compositions and methods of treating muscle atrophy and myotonic dystrophy
    Patent number: 11253607
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 22, 2022
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Michael Hood, Beatrice Diana Darimont, Rob Burke, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Compositions and methods of treating muscle atrophy and myotonic dystrophy
    Patent number: 11246941
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: February 15, 2022
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Michael Hood, Beatrice Diana Darimont, Rob Burke, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
  • Nucleic acid-polypeptide compositions and methods of inducing exon skipping
    Patent number: 11179472
    Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: November 23, 2021
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Arthur A. Levin, Andrew John Geall, Venkata Ramana Doppalapudi, Michael Caramian Cochran, Hanhua Huang, Rob Burke
  • Nucleic acid-polypeptide compositions and uses thereof
    Patent number: 11110180
    Abstract: Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: September 7, 2021
    Assignee: AVIDITY BIOSCIENCES INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, Joel Daniel Arias, David Sai-Ho Chu, Michael Caramian Cochran, Rob Burke, Philip Kovach, Barbora Malecova
  • Anti-transferrin receptor antibodies and uses thereof
    Patent number: 11028179
    Abstract: Disclosed herein, in certain embodiments, are anti-transferrin receptor antibodies, anti-transferrin receptor antibody conjugates, and pharmaceutical compositions which comprise the anti-transferrin receptor antibodies or conjugates. In some embodiments, also disclosed herein are methods of delivering a payload utilizing an anti-transferrin receptor antibody described herein, and methods of treatment with use of an anti-transferrin receptor antibody described herein.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 8, 2021
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Beatrice Diana Darimont, Venkata Ramana Doppalapudi, Rachel Johns
  • Nucleic acid-polypeptide compositions and methods of inducing exon skipping
    Patent number: 10994020
    Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: May 4, 2021
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Arthur A. Levin, Andrew John Geall, Venkata Ramana Doppalapudi, Michael Caramian Cochran, Hanhua Huang, Rob Burke